In the pola-R-CHP arm, 17 (3.9%) of the patients had grade 3/4 diarrhea compared to 8 (1.8%) in the R-CHOP arm; 52 (12%) of patients receiving the pola-R-CHP regimen had grade 3/4 anemia compared to 37 (8.4%) receiving R-CHOP; and 60 (13.8%) of the patients in the pola-R-CHP group had febrile neutropenia as compared to 35 (8%) in the R-CHOP group. Here, DDIT3 is linked to anemia (phenotype).